SHRMF

Champignon Brands

Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression

Third CRTCE Clinic effectively addresses the unmet need of depression and suicide VANCOUVER, BC, Jan. 25, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario... Read More...

Champignon Provides Update on Disclosure Review

VANCOUVER, British Columbia, Sept. 15, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review. Since the review was commenced, the Company has arranged for:Filing of business acquisition reports (coll... Read More...

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence

VANCOUVER, British Columbia, Aug. 27, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September 2020. Ketamine was declare... Read More...

Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

VANCOUVER, British Columbia, May 25, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to augment its board of directors through the appointment of accomplished business executives and ... Read More...

Le traitement à base de kétamine de Champignon sera distribué par une importante chaîne de pharmacie canadienne et la compagnie annonce la clôture de la transaction d’AltMed

VANCOUVER, Colombie-Britannique, April 30, 2020 -- Champignon Brands Inc. (« Champignon » ou la « société ») (CSE : SHRM) (FWB : 496) (OTCQB : SHRMF), une société des sciences de l’optimisation humaine concentrée sur l’application de nouveaux protocoles de traitement naturels mettant l’accent sur la médecine psychédélique afin de traiter ... Read More...

Champignon Commences U.S. Trading on the OTCQB Venture Market Under Ticker Symbol “SHRMF”

VANCOUVER, British Columbia, April 23, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to anno... Read More...

Champignon Secures Stable Psilocybin Supply Under DEA Schedule I License for TBI/PTSD Studies at the University of Miami

VANCOUVER, British Columbia, April 22, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to advan... Read More...

Champignon Appoints Former President of Red Bull Canada to Special Advisory Committee

VANCOUVER, British Columbia, April 16, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, has further bolste... Read More...

Champignon to Acquire AltMed Capital Corp.

VANCOUVER, British Columbia, April 09, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to accel... Read More...